Login to Your Account

BMS, Ambrx String Together ReCODE Deal; $24M Up Front

By Marie Powers

Friday, September 23, 2011
Ambrx Inc. became the latest jewel in the string of pearls that Bristol-Myers Squibb Co. is assembling, landing a deal worth $24 million up front for pegylated versions of the fibroblast growth factor 21 (FGF-21) protein and the relaxin hormone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription